KR20220063298A - 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 - Google Patents

전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 Download PDF

Info

Publication number
KR20220063298A
KR20220063298A KR1020227015010A KR20227015010A KR20220063298A KR 20220063298 A KR20220063298 A KR 20220063298A KR 1020227015010 A KR1020227015010 A KR 1020227015010A KR 20227015010 A KR20227015010 A KR 20227015010A KR 20220063298 A KR20220063298 A KR 20220063298A
Authority
KR
South Korea
Prior art keywords
group
compound
tumor
cell
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227015010A
Other languages
English (en)
Korean (ko)
Inventor
산지타 레이
마틴 지. 펌퍼
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Priority to KR1020237034341A priority Critical patent/KR20230147751A/ko
Publication of KR20220063298A publication Critical patent/KR20220063298A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020227015010A 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 Ceased KR20220063298A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237034341A KR20230147751A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662311697P 2016-03-22 2016-03-22
US62/311,697 2016-03-22
KR1020187030310A KR102396307B1 (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
PCT/US2017/023508 WO2017165473A1 (en) 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187030310A Division KR102396307B1 (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034341A Division KR20230147751A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Publications (1)

Publication Number Publication Date
KR20220063298A true KR20220063298A (ko) 2022-05-17

Family

ID=59899817

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227015010A Ceased KR20220063298A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020187030310A Active KR102396307B1 (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020257012794A Pending KR20250057132A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020237034341A Ceased KR20230147751A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187030310A Active KR102396307B1 (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020257012794A Pending KR20250057132A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
KR1020237034341A Ceased KR20230147751A (ko) 2016-03-22 2017-03-22 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제

Country Status (27)

Country Link
US (3) US11458213B2 (https=)
EP (3) EP4385981A1 (https=)
JP (4) JP7073270B2 (https=)
KR (4) KR20220063298A (https=)
CN (3) CN120172884A (https=)
AU (1) AU2017238181B2 (https=)
BR (1) BR112018069507A2 (https=)
CA (1) CA3018709A1 (https=)
CL (1) CL2018002683A1 (https=)
CY (1) CY1124487T1 (https=)
DK (2) DK3925952T3 (https=)
ES (2) ES2972148T3 (https=)
FI (1) FI3925952T3 (https=)
HR (2) HRP20240215T1 (https=)
HU (2) HUE065327T2 (https=)
LT (2) LT3925952T (https=)
MX (1) MX384823B (https=)
PH (1) PH12018502048A1 (https=)
PL (2) PL3925952T3 (https=)
PT (2) PT3433238T (https=)
RS (2) RS62274B1 (https=)
RU (2) RU2021115958A (https=)
SA (1) SA518400103B1 (https=)
SI (2) SI3925952T1 (https=)
TR (1) TR201813644T1 (https=)
WO (1) WO2017165473A1 (https=)
ZA (1) ZA201806389B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019002560B1 (pt) 2016-08-10 2022-08-16 Cancer Targeted Technology Llc Composto, composição farmacêutica, seus usos e método de preparação do mesmo
EP3544960A1 (en) * 2016-11-23 2019-10-02 Cancer Targeted Technology LLC Albumin-binding psma inhibitors
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
EP3494998A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
BR112020011727A2 (pt) * 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
EP3494999A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
SG11202005511VA (en) * 2017-12-13 2020-07-29 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
SG11202007180QA (en) * 2018-02-06 2020-08-28 Univ Heidelberg Fap inhibitor
KR20250126870A (ko) * 2018-02-06 2025-08-25 더 존스 홉킨스 유니버시티 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트
JP7094591B2 (ja) * 2018-03-30 2022-07-04 フューチャーケム カンパニー リミテッド 前立腺がんを診断および処置するためのｐｓｍａ標的放射性医薬品
ES3034597T3 (en) * 2018-04-27 2025-08-20 Univ Iowa Res Found Compositions for chelating metals at low temperatures
WO2020065045A1 (en) * 2018-09-28 2020-04-02 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
KR102403970B1 (ko) * 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
CN120441497A (zh) * 2019-07-02 2025-08-08 先进加速器应用意大利公司 前列腺特异性膜抗原（psma）配体及其用途
WO2021001362A1 (en) 2019-07-02 2021-01-07 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (psma) ligands and uses thereof
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
RU2730507C1 (ru) * 2019-08-27 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе
CA3176404A1 (en) * 2020-04-24 2021-10-28 Ebrahim S. Delpassand Composition, kit and method for diagnosis and treatment of prostate cancer
US20230330278A1 (en) * 2020-04-29 2023-10-19 Novartis Ag Methods for radiolabelling psma binding ligands and their kits
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
JP2023550411A (ja) * 2020-11-19 2023-12-01 ノバルティス アーゲー 前立腺特異的膜抗原（ｐｓｍａ）リガンドの合成
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
KR20240022616A (ko) * 2021-06-17 2024-02-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료
KR20230050552A (ko) * 2021-10-07 2023-04-17 (주)퓨쳐켐 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
CN120826245A (zh) * 2022-12-21 2025-10-21 梅约医学教育与研究基金会 将生物制剂与多种螯合剂组合的方法和材料
KR20260040237A (ko) 2023-07-21 2026-03-24 노파르티스 아게 Psma 표적 방사성 리간드 치료 요법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926573C (en) * 2007-06-26 2018-08-28 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
TW201034691A (en) * 2008-12-05 2010-10-01 Molecular Insight Pharm Inc Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof
EP3222617B1 (en) 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
CN113149921B (zh) * 2011-11-30 2024-11-29 约翰霍普金斯大学 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
EP3300746B1 (en) * 2013-01-14 2019-05-15 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
AU2015256002B2 (en) * 2014-05-06 2020-01-02 Northwestern University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
EP3183236B1 (en) 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
US11420910B2 (en) * 2014-10-30 2022-08-23 Katholieke Universitet Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US11520472B2 (en) * 2015-09-24 2022-12-06 Mitutoyo Corporation Inspection program editing environment including integrated alignment program planning and editing features
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

Also Published As

Publication number Publication date
CN109311827A (zh) 2019-02-05
EP3433238A1 (en) 2019-01-30
ES2972148T3 (es) 2024-06-11
US20250195700A1 (en) 2025-06-19
CL2018002683A1 (es) 2019-04-22
WO2017165473A1 (en) 2017-09-28
RS65188B1 (sr) 2024-03-29
CY1124487T1 (el) 2022-07-22
HRP20211386T1 (hr) 2021-12-10
PT3925952T (pt) 2023-12-13
PL3433238T3 (pl) 2021-12-13
KR20180134918A (ko) 2018-12-19
JP2022116028A (ja) 2022-08-09
NZ786380A (en) 2025-05-02
US20200155713A1 (en) 2020-05-21
TR201813644T1 (tr) 2018-11-21
CN120172884A (zh) 2025-06-20
HUE065327T2 (hu) 2024-05-28
US20230015736A1 (en) 2023-01-19
DK3433238T3 (da) 2021-09-06
CN114716387B (zh) 2025-04-01
FI3925952T3 (fi) 2024-02-13
EP4385981A1 (en) 2024-06-19
HUE055607T2 (hu) 2021-12-28
US11458213B2 (en) 2022-10-04
JP2024050608A (ja) 2024-04-10
PT3433238T (pt) 2021-07-28
EP3433238B1 (en) 2021-06-16
KR102396307B1 (ko) 2022-05-09
CN114716387A (zh) 2022-07-08
SA518400103B1 (ar) 2022-03-20
RU2021115958A (ru) 2021-07-12
SI3925952T1 (sl) 2024-03-29
ZA201806389B (en) 2024-01-31
EP3925952B1 (en) 2023-11-29
CA3018709A1 (en) 2017-09-28
PH12018502048A1 (en) 2019-07-01
LT3925952T (lt) 2024-01-25
RU2749399C2 (ru) 2021-06-09
CN109311827B (zh) 2022-04-12
BR112018069507A2 (pt) 2019-01-29
AU2017238181B2 (en) 2021-05-27
HRP20240215T1 (hr) 2024-04-26
KR20250057132A (ko) 2025-04-28
RU2018133693A (ru) 2020-04-22
ES2877572T3 (es) 2021-11-17
DK3925952T3 (da) 2024-02-05
EP3925952A1 (en) 2021-12-22
JP7073270B2 (ja) 2022-05-23
PL3925952T3 (pl) 2024-04-22
MX2018011519A (es) 2019-01-28
SI3433238T1 (sl) 2021-11-30
JP2019519467A (ja) 2019-07-11
EP3433238A4 (en) 2019-09-11
AU2017238181A1 (en) 2018-10-18
RS62274B1 (sr) 2021-09-30
KR20230147751A (ko) 2023-10-23
LT3433238T (lt) 2021-09-27
RU2018133693A3 (https=) 2020-04-22
JP2026021351A (ja) 2026-02-10
MX384823B (es) 2025-03-14
NZ746701A (en) 2024-12-20

Similar Documents

Publication Publication Date Title
KR102396307B1 (ko) 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
US20240140971A1 (en) Psma targeted radiohalogenated ureas for cancer radiotherapy
JP2025041719A (ja) 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
US10232058B2 (en) Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
KR102531494B1 (ko) 탄산 탈수효소 ix를 표적으로 하는 핵 영상화 및 방사선치료 제제 및 이의 용도
US20210338846A1 (en) Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
US20210040126A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
WO2016149188A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
HK1259764B (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
US10912850B2 (en) 18F-FNDP for pet imaging of soluble epoxide hydrolase (sEH)
BR122025009780A2 (pt) Compostos, método para tratar uma ou mais células ou tumores que expressam psma in vitro ou ex vivo que utiliza os ditos compostos e uso dos mesmos para tratar tumores ou células que expressam psma

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220503

Application number text: 1020187030310

Filing date: 20181019

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220602

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220701

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230510

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220701

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I